Palatin Technologies PTN

NASDAQ PTN

$12.02 -0.31 (-2.51%)

At close: Sep 10, 2026 · 4:00 PM EDT

Key Stats

Market Cap46.98 Mn

P/E-7.50

P/S3.65

Div. Yield0.00

Add ratio to table…

About

Palatin Technologies Inc is a biopharmaceutical company dedicated to discovering and developing first in class medicines that modulate the melanocortin receptor system. The melanocortin receptor system comprises five receptors designated MC1R through MC5R and influences processes such as inflammation immune response food intake metabolism and sexual function. Palatin's scientific approach involves designing receptor specific agonists that activate these receptors or antagonists that block them to achieve therapeutic effect. The company's lead programs concentrate on MC4R agonist peptides and small molecules for the treatment of obesity and metabolic related disorders. In parallel Palatin advances MC1R agonist peptides for inflammatory and autoimmune conditions including dry eye disease uveitis diabetic retinopathy and inflammatory bowel disease. Additionally the company pursues peptides and small molecules that are active at more than one melanocortin receptor to address indications such as obesity rare MC4R pathway diseases and orphan indications. Palatin employs a rational drug design strategy that uses computer aided modeling of receptor structures guided by empirical data from its peptide and small molecule libraries. This methodology enables the creation of highly selective compounds with optimized pharmacokinetic profiles. The firm advances its candidates through preclinical studies and clinical trials and then seeks to partner with larger pharmaceutical enterprises for further development manufacturing and commercialization.

Palatin generates revenue principally from product sales licensing agreements milestone payments and research collaborations. The company's sole commercialized product to date is Vyleesi an as needed subcutaneous injection for premenopausal women with hypoactive sexual desire disorder which was divested to Cosette in December 2023. The transaction delivered an upfront cash payment to Palatin and entitles the firm to receive future milestone and royalty payments contingent on Vyleesi's commercial performance. In August 2025 Palatin entered into a patent licensing arrangement with Boehringer Ingelheim International GmbH whereby Boehringer Ingelheim acquired certain patent applications covering melanocortin receptor targeted peptides for retinal disease while Palatin retained rights to its lead dry eye disease candidate PL9643. The agreement provides Palatin with immediate consideration and the potential to earn additional payments upon successful development and commercialization of the licensed inventions. Beyond these deals the company anticipates receiving cash from future collaboration and license arrangements for its obesity inflammation and other pipeline programs. Palatin also supplements its cash flow with grant awards and occasional equity financings to fund ongoing research and development activities. Because the firm does not own large scale manufacturing facilities it relies on contract manufacturing organizations to produce clinical trial material and anticipates relying on partners for commercial scale production.

Palatin competes in several crowded therapeutic areas where larger pharmaceutical and biotechnology companies enjoy substantial financial technical and marketing resources. In the obesity market its MC4R agonist candidates contend with well established GLP 1 based therapies such as Wegovy and Ozempic from Novo Nordisk and Eli Lilly as well as the melanocortin agonist setmelanotide marketed by Rhythm Pharmaceuticals under the brand name Imcivree. Additional competition emerges from numerous other firms developing obesity treatments including Sanofi Merck Roche Pfizer Regeneron Altimmune and many academic spin offs. In the dry eye disease arena Palatin's lead candidate PL9643 faces competition from topical immunosuppressants such as Allergan's Restasis and Novartis' Xiidra and from a broad pipeline of investigational agents that include perfluorohexyloctane cyclosporine TRPM8 selective agonist aldehyde derivative partial TrkA receptor agonist cardiolipin peroxidation inhibitor tumor necrosis factor antagonists alpha 2 adrenergic receptor agonist calcineurin inhibitors and nicotinic receptor agonists. For inflammatory bowel disease the oral PL8177 molecule competes against aminosalicylates corticosteroids biologics including tumor necrosis factor inhibitors Janus kinase inhibitors monoclonal antibodies FXR inhibitor integrin inhibitors S1P1 receptor modulators anti TL1A monoclonal antibodies DHODH inhibitor HIF 1a stabilizer and LANCL2 receptor modulator. Despite these formidable rivals Palatin differentiates itself through its proprietary melanocortin receptor platform its extensive estate of issued and pending patents covering peptide and small molecule agonists and its focus on first in class mechanisms that modulate endogenous immune and metabolic pathways. The company's business model of forming strategic alliances with established pharmaceutical firms allows it to leverage external capabilities while preserving intellectual property rights and sharing development costs.

Palatin's ultimate customers are patients who suffer from obesity metabolic disorders inflammatory ocular diseases inflammatory bowel disease or sexual dysfunction. The company's product candidates are intended for individuals seeking weight loss relief from excess body weight relief from ocular irritation redness discharge and blurred vision associated with dry eye disease relief from inflammatory bowel symptoms such as abdominal pain diarrhea and rectal bleeding and relief from hypoactive sexual desire disorder characterized by diminished sexual interest and distress. In addition to patient populations Palatin interacts with specific corporate partners that provide funding development expertise and commercialization reach. Notable collaborators cited in the filing include Cosette which acquired the Vyleesi product and Boehringer Ingelheim which obtained rights to certain retinal disease patents. The firm also works with contract research organizations contract manufacturers and academic institutions to support preclinical testing clinical trial execution and regulatory strategy. While the final end users are individual patients the immediate customers for Palatin's outlicensed assets are pharmaceutical and biotechnology companies that assume responsibility for later stage development manufacturing marketing and sales of the licensed compounds.

Investment Thesis

▲ Bull case

Palatin Technologies' strategic pivot towards MC4R-selective obesity therapeutics for rare genetic disorders represents a compelling and underappreciated growth trajectory that the market is overlooking due to near-term financial volatility. The company's focus on hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome targets populations with near-total absence of approved pharmacologic options, creating a clear path to premium pricing and rapid adoption should clinical success be demonstrated. Unlike broader obesity drugs burdened by tolerability issues, Palatin's engineered selectivity for MC4R over MC1R directly addresses historical liabilities like hyperpigmentation, potentially enabling chronic use in pediatric and adolescent populations—a critical advantage in syndromes where lifelong management is essential. This differentiation is not incremental but foundational to capturing value in niches where payers prioritize long-term safety over marginal efficacy gains, positioning Palatin to command partnership interest from larger biopharma seeking de-risked entry into rare obesity. The recent Nasdaq uplisting, while framed as a liquidity play, significantly expands institutional accessibility and analyst coverage, which could catalyze re-rating as investors recognize the platform's applicability beyond rare indications into subsets of common obesity where melanocortin pathway dysfunction plays a role. Furthermore, the company's cash runway extending to June 30, 2027—bolstered by the $16.9 million net proceeds from the November 2025 offering and non-cash debt cancellation from the PL9643 sublicensing—provides ample time to achieve dual IND submissions (peptide Q4 CY2026, oral H1 CY2027) without dilutive financing, preserving optionality for partnership discussions at inflection points. The market is failing to assign adequate probability weight to the near-term milestones: successful IND filings would validate years of preclinical optimization and trigger potential milestone payments from existing collaborations, transforming Palatin from a cash-burning biotech into a near-term revenue-generating entity with tangible clinical progress.
Palatin's obesity pipeline is advancing with de-risked clinical pathways that the market is ignoring due to fixation on quarterly losses, despite clear evidence of operational execution and scientific validation. The company has consistently hit self-imposed timelines: PL7737 entered clinical evaluation in H1 CY2026 as stated in the February 2026 update, and the once-weekly peptide agonist remains on track for IND submission in Q4 CY2026, demonstrating disciplined progress in a sector notorious for delays. This reliability stems from Palatin's deep expertise in melanocortin receptor pharmacology, allowing rational design of candidates with improved potency and reduced off-target effects—attributes directly correlated to better tolerability and adherence in chronic therapy, which are make-or-break factors in rare obesity syndromes where caregiver burden is high. The sublicensing of PL9643 (an MC1R agonist for dry eye) not only provided immediate non-dilutive value through $3.8 million in debt cancellation but also validates the broader MCR platform's commercial appeal, suggesting that success in obesity could unlock similar partnership economics. Crucially, the recognition of $3.9 million in collaboration revenue in Q1 FY2026 from the Altanispac Agreement—despite minimal promotional emphasis—proves Palatin's ability to monetize its platform through structured deals, a capability the market discounts given its historical reliance on dilutive financing. These revenue inflections, combined with rising cash balances ($10.2 million as of March 31, 2026) and reduced net losses ($1.4 million in Q3 FY2026 vs $4.8 million prior year), indicate an inflection point where operating leverage could emerge sooner than anticipated if clinical data supports partner engagement. The market's focus on GAAP losses obscures the underlying value creation in the pipeline, where each IND submission represents a discrete, tradable asset with potential for significant upside upon positive readouts.
Structural shifts in the rare obesity treatment landscape are creating a tailwind for Palatin's differentiated approach that the market is failing to incorporate into its valuation framework, instead viewing the company through the lens of crowded obesity therapeutics. Regulatory agencies are increasingly receptive to therapies targeting monogenic obesity pathways, as evidenced by recent approvals for setmelanotide in specific Bardet-Biedl and PWS subsets, establishing a precedent for mechanism-based acceptance and reducing regulatory risk for novel MC4R agonists. This environment favors Palatin's precision medicine strategy over broad-acting agonists, as regulators and payers demand evidence of target engagement in genetically defined populations—exactly where Palatin's clinical trial designs are focused. Concurrently, the failure of GLP-1-based therapies to adequately address hyperphagia in neuroendocrine obesity disorders has created a clear unmet need that MC4R agonism is uniquely positioned to fill, given its central role in melanocortin signaling dysregulation in hypothalamic damage and genetic syndromes. Palatin's emphasis on long-term usability directly addresses the critical limitation of current options: intermittent use due to side effects, which undermines efficacy in conditions requiring constant satiety regulation. As awareness grows among specialists treating these rare disorders, early adoption could establish Palatin's candidates as standard of care before broader obesity markets are even considered, creating a defensible beachhead with loyal prescriber networks. The market's myopic focus on competition from tirzepatide and semaglutide ignores that these drugs are largely ineffective in the specific patient populations Palatin targets, where melanocortin pathway dysfunction is the primary driver—not leptin resistance or gastric emptying—rendering direct competition irrelevant and allowing Palatin to operate in a de facto exclusivity zone until pan-obesity agents demonstrate efficacy in these refractory subtypes.

Palatin Technologies' strategic pivot towards MC4R-selective obesity therapeutics for rare genetic disorders represents a compelling and underappreciated growth trajectory that the market is overlooking due to near-term financial volatility. The company's focus on hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome targets populations with near-total absence of approved pharmacologic options, creating a clear path to premium pricing and rapid adoption should clinical success be demonstrated. Unlike broader obesity drugs burdened by tolerability issues, Palatin's engineered selectivity for MC4R over MC1R directly addresses historical liabilities like hyperpigmentation, potentially enabling chronic use in pediatric and adolescent populations—a critical advantage in syndromes where lifelong management is essential. This differentiation is not incremental but foundational to capturing value in niches where payers prioritize long-term safety over marginal efficacy gains, positioning Palatin to command partnership interest from larger biopharma seeking de-risked entry into rare obesity. The recent Nasdaq uplisting, while framed as a liquidity play, significantly expands institutional accessibility and analyst coverage, which could catalyze re-rating as investors recognize the platform's applicability beyond rare indications into subsets of common obesity where melanocortin pathway dysfunction plays a role. Furthermore, the company's cash runway extending to June 30, 2027—bolstered by the $16.9 million net proceeds from the November 2025 offering and non-cash debt cancellation from the PL9643 sublicensing—provides ample time to achieve dual IND submissions (peptide Q4 CY2026, oral H1 CY2027) without dilutive financing, preserving optionality for partnership discussions at inflection points. The market is failing to assign adequate probability weight to the near-term milestones: successful IND filings would validate years of preclinical optimization and trigger potential milestone payments from existing collaborations, transforming Palatin from a cash-burning biotech into a near-term revenue-generating entity with tangible clinical progress.
Palatin's obesity pipeline is advancing with de-risked clinical pathways that the market is ignoring due to fixation on quarterly losses, despite clear evidence of operational execution and scientific validation. The company has consistently hit self-imposed timelines: PL7737 entered clinical evaluation in H1 CY2026 as stated in the February 2026 update, and the once-weekly peptide agonist remains on track for IND submission in Q4 CY2026, demonstrating disciplined progress in a sector notorious for delays. This reliability stems from Palatin's deep expertise in melanocortin receptor pharmacology, allowing rational design of candidates with improved potency and reduced off-target effects—attributes directly correlated to better tolerability and adherence in chronic therapy, which are make-or-break factors in rare obesity syndromes where caregiver burden is high. The sublicensing of PL9643 (an MC1R agonist for dry eye) not only provided immediate non-dilutive value through $3.8 million in debt cancellation but also validates the broader MCR platform's commercial appeal, suggesting that success in obesity could unlock similar partnership economics. Crucially, the recognition of $3.9 million in collaboration revenue in Q1 FY2026 from the Altanispac Agreement—despite minimal promotional emphasis—proves Palatin's ability to monetize its platform through structured deals, a capability the market discounts given its historical reliance on dilutive financing. These revenue inflections, combined with rising cash balances ($10.2 million as of March 31, 2026) and reduced net losses ($1.4 million in Q3 FY2026 vs $4.8 million prior year), indicate an inflection point where operating leverage could emerge sooner than anticipated if clinical data supports partner engagement. The market's focus on GAAP losses obscures the underlying value creation in the pipeline, where each IND submission represents a discrete, tradable asset with potential for significant upside upon positive readouts.
Structural shifts in the rare obesity treatment landscape are creating a tailwind for Palatin's differentiated approach that the market is failing to incorporate into its valuation framework, instead viewing the company through the lens of crowded obesity therapeutics. Regulatory agencies are increasingly receptive to therapies targeting monogenic obesity pathways, as evidenced by recent approvals for setmelanotide in specific Bardet-Biedl and PWS subsets, establishing a precedent for mechanism-based acceptance and reducing regulatory risk for novel MC4R agonists. This environment favors Palatin's precision medicine strategy over broad-acting agonists, as regulators and payers demand evidence of target engagement in genetically defined populations—exactly where Palatin's clinical trial designs are focused. Concurrently, the failure of GLP-1-based therapies to adequately address hyperphagia in neuroendocrine obesity disorders has created a clear unmet need that MC4R agonism is uniquely positioned to fill, given its central role in melanocortin signaling dysregulation in hypothalamic damage and genetic syndromes. Palatin's emphasis on long-term usability directly addresses the critical limitation of current options: intermittent use due to side effects, which undermines efficacy in conditions requiring constant satiety regulation. As awareness grows among specialists treating these rare disorders, early adoption could establish Palatin's candidates as standard of care before broader obesity markets are even considered, creating a defensible beachhead with loyal prescriber networks. The market's myopic focus on competition from tirzepatide and semaglutide ignores that these drugs are largely ineffective in the specific patient populations Palatin targets, where melanocortin pathway dysfunction is the primary driver—not leptin resistance or gastric emptying—rendering direct competition irrelevant and allowing Palatin to operate in a de facto exclusivity zone until pan-obesity agents demonstrate efficacy in these refractory subtypes.

▼ Bear case

Palatin Technologies faces significant near-term execution risks in its obesity program that the market is underestimating, particularly regarding the feasibility and timelines of its IND submissions despite optimistic guidance. The company's reliance on peptide-based once-weekly injectable and oral small-molecule MC4R agonists presents substantial technical hurdles, including potential challenges in achieving sufficient half-life for weekly dosing without accumulation-related toxicity, and overcoming the historical notoriously flat dose-response curves associated with melanocortin receptor targeting, which have doomed prior obesity programs. While Palatin emphasizes improved selectivity to reduce MC1R-mediated hyperpigmentation, preclinical data does not guarantee clinical translation, and any residual off-target activity could still manifest in chronic use scenarios, especially in pediatric populations prevalent in Prader-Willi and Bardet-Biedl syndromes where long-term safety is paramount. The IND timelines—Q4 CY2026 for the peptide and H1 CY2027 for the oral candidate—are aggressive given the complexity of IND-enabling studies required for novel chemical entities, including comprehensive genotoxicity, carcinogenicity, and reproductive toxicology packages that frequently delay submissions. Furthermore, the company's cash runway extension to June 30, 2027 assumes no delays in development or unexpected increases in burn rate, yet operating expenses rose to $5.5 million in Q3 FY2026 from $4.8 million prior year, driven by higher compensation and professional fees—a trend that could accelerate as clinical activities intensify, potentially consuming cash faster than projected if IND-enabling studies require unanticipated repeats or expansions. The market may be pricing in successful IND filings as a near-term certainty, but the historical success rate for IND submissions in obesity therapeutics is well below 50%, and Palatin has no prior experience bringing an MC4R obesity candidate to this stage, increasing the likelihood of setbacks that would necessitate dilutive financing well before the projected runway ends.
Palatin's partnership and out-licensing strategy, while presented as a near-term value catalyst, carries substantial uncertainty that the market is overlooking, particularly regarding the commercial viability of its MC4R obesity candidates in the face of entrenched competitors and reimbursement challenges. The company's dependence on forming marketing collaborations with industry leaders to maximize commercial potential introduces significant execution risk, as larger biopharma may hesitate to partner without compelling Phase 2 proof-of-concept data demonstrating clear superiority over existing options like setmelanotide or emerging GLP-1/GIP dual agonists in the specific rare obesity indications Palatin targets. Even if IND submissions are successful, the path to Phase 2 readouts extends well beyond the current cash runway, meaning any partnership would likely occur at a very early stage, resulting in unfavorable terms—low upfront payments, high milestones, and significant royalty discounts—that would minimally impact near-term valuation. Moreover, the obesity landscape is evolving rapidly, with multiple companies advancing MC4R-focused programs (including Rhythm Pharmaceuticals' setmelanotide lifecycle management and newer entrants), increasing the risk that Palatin's candidates, despite improved selectivity, may not demonstrate sufficient differentiation to warrant premium partnership interest. The sublicensing of PL9643, while providing immediate balance sheet relief, involved an MC1R asset for dry eye—a non-core program with limited comparability to obesity therapeutics—and its success does not predict outcomes for the obesity pipeline, where safety and efficacy barriers are substantially higher. The market may be overestimating the likelihood and value of near-term deals based on platform validation from unrelated assets, ignoring that obesity partnerships require late-phase clinical data or at least robust Phase 2 signals, which Palatin is unlikely to generate before 2028 at the earliest under current timelines.
Structural challenges in the rare obesity market itself pose a material threat to Palatin's commercial prospects that the market is ignoring, particularly the limited addressable patient populations and pricing constraints inherent in ultra-orphan indications. While hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome represent significant unmet medical need, their combined prevalence is estimated in the low tens of thousands globally—far too small to support a standalone commercial infrastructure without partnership, yet large enough to attract competition from specialized rare disease players. This creates a pincer movement: too big to ignore but too small to justify major investment from large pharma without near-term blockbuster potential, which Palatin's candidates are unlikely to deliver given the modest efficacy expected from MC4R monotherapy in complex neurodevelopmental disorders. Payers are increasingly scrutinizing ultra-orphan drug pricing, demanding robust long-term outcomes data that Palatin will struggle to generate quickly due to the chronic nature of these conditions and the difficulty of conducting large, lengthy trials in dispersed patient populations. Furthermore, the phenotypic heterogeneity within these syndromes—particularly in Prader-Willi syndrome where hyperphagia severity varies widely—could dilute clinical trial signals, requiring larger sample sizes to achieve statistical significance and increasing development costs and timelines beyond current projections. The market may be assuming that success in one rare obesity indication will translate broadly across the portfolio, but differences in underlying pathophysiology (e.g., hypothalamic damage vs. genetic imprinting defects) could necessitate separate development tracks, fracturing focus and resources. Without clear evidence of dose-dependent target engagement or biomarkers predictive of response, Palatin risks investing heavily in candidates that fail to move the needle in clinically meaningful ways, leaving it with scientifically interesting but commercially non-viable assets in a niche where failure to partner equates to de facto abandonment due to insufficient scale for solo commercialization.

Palatin Technologies faces significant near-term execution risks in its obesity program that the market is underestimating, particularly regarding the feasibility and timelines of its IND submissions despite optimistic guidance. The company's reliance on peptide-based once-weekly injectable and oral small-molecule MC4R agonists presents substantial technical hurdles, including potential challenges in achieving sufficient half-life for weekly dosing without accumulation-related toxicity, and overcoming the historical notoriously flat dose-response curves associated with melanocortin receptor targeting, which have doomed prior obesity programs. While Palatin emphasizes improved selectivity to reduce MC1R-mediated hyperpigmentation, preclinical data does not guarantee clinical translation, and any residual off-target activity could still manifest in chronic use scenarios, especially in pediatric populations prevalent in Prader-Willi and Bardet-Biedl syndromes where long-term safety is paramount. The IND timelines—Q4 CY2026 for the peptide and H1 CY2027 for the oral candidate—are aggressive given the complexity of IND-enabling studies required for novel chemical entities, including comprehensive genotoxicity, carcinogenicity, and reproductive toxicology packages that frequently delay submissions. Furthermore, the company's cash runway extension to June 30, 2027 assumes no delays in development or unexpected increases in burn rate, yet operating expenses rose to $5.5 million in Q3 FY2026 from $4.8 million prior year, driven by higher compensation and professional fees—a trend that could accelerate as clinical activities intensify, potentially consuming cash faster than projected if IND-enabling studies require unanticipated repeats or expansions. The market may be pricing in successful IND filings as a near-term certainty, but the historical success rate for IND submissions in obesity therapeutics is well below 50%, and Palatin has no prior experience bringing an MC4R obesity candidate to this stage, increasing the likelihood of setbacks that would necessitate dilutive financing well before the projected runway ends.
Palatin's partnership and out-licensing strategy, while presented as a near-term value catalyst, carries substantial uncertainty that the market is overlooking, particularly regarding the commercial viability of its MC4R obesity candidates in the face of entrenched competitors and reimbursement challenges. The company's dependence on forming marketing collaborations with industry leaders to maximize commercial potential introduces significant execution risk, as larger biopharma may hesitate to partner without compelling Phase 2 proof-of-concept data demonstrating clear superiority over existing options like setmelanotide or emerging GLP-1/GIP dual agonists in the specific rare obesity indications Palatin targets. Even if IND submissions are successful, the path to Phase 2 readouts extends well beyond the current cash runway, meaning any partnership would likely occur at a very early stage, resulting in unfavorable terms—low upfront payments, high milestones, and significant royalty discounts—that would minimally impact near-term valuation. Moreover, the obesity landscape is evolving rapidly, with multiple companies advancing MC4R-focused programs (including Rhythm Pharmaceuticals' setmelanotide lifecycle management and newer entrants), increasing the risk that Palatin's candidates, despite improved selectivity, may not demonstrate sufficient differentiation to warrant premium partnership interest. The sublicensing of PL9643, while providing immediate balance sheet relief, involved an MC1R asset for dry eye—a non-core program with limited comparability to obesity therapeutics—and its success does not predict outcomes for the obesity pipeline, where safety and efficacy barriers are substantially higher. The market may be overestimating the likelihood and value of near-term deals based on platform validation from unrelated assets, ignoring that obesity partnerships require late-phase clinical data or at least robust Phase 2 signals, which Palatin is unlikely to generate before 2028 at the earliest under current timelines.
Structural challenges in the rare obesity market itself pose a material threat to Palatin's commercial prospects that the market is ignoring, particularly the limited addressable patient populations and pricing constraints inherent in ultra-orphan indications. While hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome represent significant unmet medical need, their combined prevalence is estimated in the low tens of thousands globally—far too small to support a standalone commercial infrastructure without partnership, yet large enough to attract competition from specialized rare disease players. This creates a pincer movement: too big to ignore but too small to justify major investment from large pharma without near-term blockbuster potential, which Palatin's candidates are unlikely to deliver given the modest efficacy expected from MC4R monotherapy in complex neurodevelopmental disorders. Payers are increasingly scrutinizing ultra-orphan drug pricing, demanding robust long-term outcomes data that Palatin will struggle to generate quickly due to the chronic nature of these conditions and the difficulty of conducting large, lengthy trials in dispersed patient populations. Furthermore, the phenotypic heterogeneity within these syndromes—particularly in Prader-Willi syndrome where hyperphagia severity varies widely—could dilute clinical trial signals, requiring larger sample sizes to achieve statistical significance and increasing development costs and timelines beyond current projections. The market may be assuming that success in one rare obesity indication will translate broadly across the portfolio, but differences in underlying pathophysiology (e.g., hypothalamic damage vs. genetic imprinting defects) could necessitate separate development tracks, fracturing focus and resources. Without clear evidence of dose-dependent target engagement or biomarkers predictive of response, Palatin risks investing heavily in candidates that fail to move the needle in clinically meaningful ways, leaving it with scientifically interesting but commercially non-viable assets in a niche where failure to partner equates to de facto abandonment due to insufficient scale for solo commercialization.

Product and Service Breakdown of Revenue (2020)

Peer group

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	AMGN	Amgen Inc	primary	206.44 Bn	23.61	5.42	62.75 Bn
2	GILD	Gilead Sciences, Inc.	primary	179.97 Bn	-62.17	5.91	28.66 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	primary	130.57 Bn	29.64	10.37	-
4	REGN	Regeneron Pharmaceuticals, Inc.	primary	81.63 Bn	18.86	5.25	1.99 Bn
5	ARGX	Argenx Se	primary	60.34 Bn	35.18	11.55	-
6	MRNA	Moderna, Inc.	primary	54.37 Bn	-17.25	24.40	0.59 Bn
7	ALNY	Alnylam Pharmaceuticals, Inc.	primary	33.07 Bn	42.69	6.88	-
8	BIIB	Biogen Inc.	primary	31.84 Bn	38.15	3.17	8.09 Bn

Palatin Technologies PTN

About

Investment Thesis

Product and Service Breakdown of Revenue (2020)

Peer Comparison

Create an account

Sign In

Reset Password